What are the side effects of Platinib/Pujihua? What issues should patients pay attention to

As a targeted drug, Pralsetinib provides an important treatment option for patients with non-small cell lung cancer (NSCLC) and thyroid cancer with RET gene rearrangement mutations, but it may also cause some side effects. When using platinib, patients need to understand its common side effects and conduct effective monitoring and management under the guidance of a doctor.

Common side effects of Platinib include fatigue, high blood pressure, decreased appetite, constipation, nausea, and headache. Some patients may experience mild gastrointestinal discomfort, such as nausea, vomiting, and diarrhea. It is worth noting that hypertension is one of the more common side effects during the use of platinib, especially for patients with a history of hypertension, and blood pressure needs to be monitored regularly during treatment. If a patient notices an increase in blood pressure, additional interventions may be needed, such as the use of antihypertensive medications.

Another side effect that needs attention is abnormal liver function. Platinib may cause an increase in liver function indicators, so liver function needs to be checked regularly during treatment. If liver function is abnormal, the doctor may adjust the dose or suspend the use of platinib until liver function returns to normal.

For some patients, Platinib may also cause skin reactions such as rash and mouth ulcers. This type of reaction is usually mild, but if symptoms worsen, patients should communicate with their doctor in time, and the drug treatment plan may need to be adjusted.

In addition, platinib may affect bone marrow function, leading to a decrease in blood cells, especially white blood cells and platelets. When patients are using platinib, especially during long-term treatment, regular blood tests should be performed to ensure that blood cell levels remain within a safe range.

Keyword tags: Pralsetinib, Pralsetinib, side effects, hypertension, gastrointestinal discomfort, liver function, rash, oral ulcers, cytopenias

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf